Advancements in dendritic cell vaccination: enhancing efficacy and optimizing combinatorial strategies for the treatment of glioblastoma

被引:2
|
作者
Subtirelu, Robert C. [1 ]
Teichner, Eric M. [2 ]
Ashok, Arjun [2 ]
Parikh, Chitra [2 ]
Talasila, Sahithi [2 ]
Matache, Irina-Mihaela [3 ]
Alnemri, Ahab G. [1 ]
Anderson, Victoria [2 ]
Shahid, Osmaan [1 ]
Mannam, Sricharvi [1 ]
Lee, Andrew [1 ]
Werner, Thomas [1 ]
Revheim, Mona-Elisabeth [4 ,5 ]
Alavi, Abass [1 ]
机构
[1] Hosp Univ Penn, Dept Radiol, Philadelphia, PA USA
[2] Thomas Jefferson Univ, Sidney Kimmel Med Coll, Philadelphia, PA USA
[3] Carol Davila Univ Med & Pharm, Dept Physiol, Fac Med, Bucharest, Romania
[4] Oslo Univ Hosp, Div Orthoped Surg, Oslo, Norway
[5] Univ Oslo, Inst Clin Med, Fac Med, Oslo, Norway
来源
FRONTIERS IN NEUROLOGY | 2023年 / 14卷
关键词
glioblastoma; dendritic cell vaccination; positron emission tomography; antigen loading; immunotherapy; CYTOTOXIC T-LYMPHOCYTES; MALIGNANT GLIOMA; TUMOR-ANTIGEN; BRAIN-TUMOR; FDG-PET; MULTIFORME; VACCINES; IMMUNOTHERAPY; RESPONSES; SURVIVAL;
D O I
10.3389/fneur.2023.1271822
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Glioblastomas (GBM) are highly invasive, malignant primary brain tumors. The overall prognosis is poor, and management of GBMs remains a formidable challenge, necessitating novel therapeutic strategies such as dendritic cell vaccinations (DCVs). While many early clinical trials demonstrate an induction of an antitumoral immune response, outcomes are mixed and dependent on numerous factors that vary between trials. Optimization of DCVs is essential; the selection of GBM-specific antigens and the utilization of 18F-fludeoxyglucose Positron Emission Tomography (FDG-PET) may add significant value and ultimately improve outcomes for patients undergoing treatment for glioblastoma. This review provides an overview of the mechanism of DCV, assesses previous clinical trials, and discusses future strategies for the integration of DCV into glioblastoma treatment protocols. To conclude, the review discusses challenges associated with the use of DCVs and highlights the potential of integrating DCV with standard therapies.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] Clinical applications of dendritic cell vaccination in the treatment of cancer
    Lee D. Cranmer
    Katrina T. Trevor
    Evan M. Hersh
    Cancer Immunology, Immunotherapy, 2004, 53 : 275 - 306
  • [22] Cytokine responsiveness of CD8(+) T cells is a reproducible biomarker for the clinical efficacy of dendritic cell vaccination in glioblastoma patients
    Everson, Richard G.
    Jin, Richard M.
    Wang, Xiaoyan
    Safaee, Michael
    Scharnweber, Rudi
    Lisiero, Dominique N.
    Soto, Horacio
    Liau, Linda M.
    Prins, Robert M.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2014, 2
  • [23] Clinical applications of dendritic cell vaccination in the treatment of cancer
    Lee, DC
    Trevor, KT
    Hersh, EM
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2004, 53 (04) : 275 - 306
  • [24] Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination
    Galea-Lauri, J
    Wells, JW
    Darling, D
    Harrison, P
    Farzaneh, F
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2004, 53 (11) : 963 - 977
  • [25] Dendritic-cell- and peptide-based vaccination strategies for glioma
    Yamanaka, Ryuya
    NEUROSURGICAL REVIEW, 2009, 32 (03) : 265 - 273
  • [26] Enhancing treatment efficacy of glioblastoma cell lines by adding tumor treating fields (TTFields) to temozolomide and lomustine
    Fishman, Hila
    Monin, Roni
    Dor-On, Eyal
    Haber, Adi
    Giladi, Moshe
    Weinberg, Uri
    Palti, Yoram
    CANCER RESEARCH, 2023, 83 (07)
  • [27] Dendritic cell vaccination and other strategies to tip the balance of the immune system
    Schaft, Niels
    Birkholz, Katrin
    Hofmann, Christian
    Schmid, Martina
    Theiner, Gabi
    Doerrie, Jan
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2008, 57 (06) : 913 - 928
  • [28] Dendritic-cell- and peptide-based vaccination strategies for glioma
    Ryuya Yamanaka
    Neurosurgical Review, 2009, 32 : 265 - 273
  • [29] Dendritic Cell-Based and Other Vaccination Strategies for Pediatric Cancer
    de Bruijn, Severine
    Anguille, Sebastien
    Verlooy, Joris
    Smits, Evelien L.
    van Tendeloo, Viggo E.
    de Laere, Maxime
    Norga, Koenraad
    Berneman, Zwi N.
    Lion, Eva
    CANCERS, 2019, 11 (09)
  • [30] Natural Killer Cells: The Secret Weapon in Dendritic Cell Vaccination Strategies
    Van Elssen, Catharina H. M. J.
    Oth, Tammy
    Germeraad, Wilfred T. V.
    Bos, Gerard M. J.
    Vanderlocht, Joris
    CLINICAL CANCER RESEARCH, 2014, 20 (05) : 1095 - 1103